인실리코 신약 개발 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global in-silico drug discovery market size is expected to reach USD 10.34 Billion in 2034 from USD 4.36 Billion in 2025, growing at a CAGR of 10.07% during 2026-2034.The Global In-Silico Drug Discovery Market is rapidly gaining momentum as pharmaceutical companies increasingly adopt computational methods to accelerate drug development. In-silico technologies use computer simulations, artificial intelligence, and advanced algorithms to identify potential drug candidates and predict their biological behavior. This approach significantly reduces the time and cost associated with traditional laboratory-based drug discovery processes.

One of the major growth drivers is the rising demand for faster and more efficient drug development, particularly in response to emerging diseases and complex medical conditions. Pharmaceutical and biotechnology companies are integrating artificial intelligence and machine learning into drug discovery workflows to enhance accuracy and efficiency. Additionally, increasing investments in bioinformatics and computational biology are further strengthening the market.

Looking ahead, the in-silico drug discovery market is expected to expand as digital technologies continue to transform pharmaceutical research. The growing use of big data analytics and cloud computing in drug development will enhance predictive modeling capabilities. As the healthcare industry seeks innovative solutions to accelerate therapeutic discoveries, the adoption of in-silico methods is likely to increase significantly.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Component

• Software
• Services

By Drug-Discovery Phase

• Target Identification & Validation
• Hit Identification
• Lead Optimization
• Candidate Validation

By Therapeutic Area

• Oncology
• Neurology
• Cardiovascular
• Infectious Diseases
• Metabolic Disorders

By End User

• Pharmaceutical Companies
• Biotechnology Firms
• Academic & Research Institutes
• CROs

By Deployment

• On-premise
• Cloud-based

COMPANIES PROFILED

• Schrodinger, Inc., Exscientia plc, Recursion Pharmaceuticals, Inc., Insilico Medicine, BenevolentAI, Atomwise, Inc., Relay Therapeutics, Inc., XtalPi Inc., Cyclica Inc., Valence Discovery, Isomorphic Labs, Owkin, NVIDIA Corporation, IBM Corporation, Microsoft Corporation, Google DeepMind, Certara, Inc., Dassault Systemes SE, Crown Bioscience, Evotec SE

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL IN-SILICO DRUG DISCOVERY MARKET: BY COMPONENT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Component
• 4.2. Software Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL IN-SILICO DRUG DISCOVERY MARKET: BY DRUG-DISCOVERY PHASE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug-discovery Phase
• 5.2. Target Identification & Validation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Hit Identification Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Lead Optimization Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Candidate Validation Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL IN-SILICO DRUG DISCOVERY MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Therapeutic Area
• 6.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Cardiovascular Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Metabolic Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL IN-SILICO DRUG DISCOVERY MARKET: BY END USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End User
• 7.2. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Biotechnology Firms Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Academic & Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. CROs Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL IN-SILICO DRUG DISCOVERY MARKET: BY DEPLOYMENT 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Deployment
• 8.2. On-premise Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Cloud-based Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL IN-SILICO DRUG DISCOVERY MARKET: BY REGION 2022-2034 (USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Component
  • 9.2.2 By Drug-discovery Phase
  • 9.2.3 By Therapeutic Area
  • 9.2.4 By End User
  • 9.2.5 By Deployment
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Component
  • 9.3.2 By Drug-discovery Phase
  • 9.3.3 By Therapeutic Area
  • 9.3.4 By End User
  • 9.3.5 By Deployment
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Spain
  • 9.3.11 Russia
  • 9.3.12 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Component
  • 9.4.2 By Drug-discovery Phase
  • 9.4.3 By Therapeutic Area
  • 9.4.4 By End User
  • 9.4.5 By Deployment
  • 9.4.6 China
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 India
  • 9.4.10 Australia
  • 9.4.11 South East Asia
  • 9.4.12 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Component
  • 9.5.2 By Drug-discovery Phase
  • 9.5.3 By Therapeutic Area
  • 9.5.4 By End User
  • 9.5.5 By Deployment
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Component
  • 9.6.2 By Drug-discovery Phase
  • 9.6.3 By Therapeutic Area
  • 9.6.4 By End User
  • 9.6.5 By Deployment
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL IN-SILICO DRUG DISCOVERY INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 SchrodingerInc
  • 11.2.2 Exscientia Plc
  • 11.2.3 Recursion PharmaceuticalsInc
  • 11.2.4 Insilico Medicine
  • 11.2.5 BenevolentAI
  • 11.2.6 AtomwiseInc
  • 11.2.7 Relay TherapeuticsInc
  • 11.2.8 XtalPi Inc
  • 11.2.9 Cyclica Inc
  • 11.2.10 Valence Discovery
  • 11.2.11 Isomorphic Labs
  • 11.2.12 Owkin
  • 11.2.13 NVIDIA Corporation
  • 11.2.14 IBM Corporation
  • 11.2.15 Microsoft Corporation
  • 11.2.16 Google DeepMind
  • 11.2.17 CertaraInc
  • 11.2.18 Dassault Systemes SE
  • 11.2.19 Crown Bioscience
  • 11.2.20 Evotec SE